GNMX - Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies. The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development. Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization.
As of Nov 13, 2026: spot at $34.94, max pain $37.00, GEX (assumed dealer book) -$545 of delta per 1% move.
Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (1 expiration, through Nov 20, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $1.9M
- Beta
- 2.27
- 52-Week Range
- 23.88-39.86
- IPO Date
- May 6, 2026
- Exchange
- CBOE
What GNMX Looks Like to Options Traders Today
the assumed dealer book's GEX is negative (-$545 of delta per 1% move): its hedging goes with the trend, amplifying realized volatility and accelerating directional moves where real dealers are positioned like the book; the 25-delta skew (0.028) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The GNMX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.
GNMX fund facts: expense ratio 0.35%, assets under management $1.2M, NAV $35.36 as of the data source's update on Nov 13, 2026, 59 holdings in its latest file, launched May 5, 2026, issued by Corgi Funds. See the GNMX holdings.
Frequently asked GNMX overview questions
- What is GNMX?
- GNMX is the ticker symbol for Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF, an listed exchange-traded fund. GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies. The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development. Listed on CBOE. GNMX is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
- What does the GNMX options snapshot look like today?
- As of Nov 13, 2026, the GNMX options snapshot shows spot at $34.94, max pain $37.00, GEX (assumed dealer book) -$545 of delta per 1% move. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are GNMX's key statistics?
- Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF (GNMX) carries a market capitalization of $1.9M, 52-week range of 23.88-39.86. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
- What sector or industry does GNMX belong to?
- Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF operates in the Financial Services sector, in the Asset Management industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare GNMX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the GNMX data on this page?
- The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.